Newsfeeds - Spark Newswire

2 minute read

FDA
News

Petra Acquisition M&A Partner Revelation Biosciences Announces Initiation Of Phase 1b Clinical Study Of REVTx-99 For Experimental Treatment Of Allergic Rhinitis And Chronic Nasal Congestion

Today, 10:39 PM

Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today the

PAICU

2 minute read

Petra Acquisition Corp. SPAC Merger Partner, Revelation Biosciences, Reports Received Approval To Initiate Phase 2b Viral Challenge Study Of REVTx 99 For Treatment To Prevent Respiratory Viral Infections

By Benzinga Newsdesk

Today, 10:39 PM

- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) --

PAICU

1 minute read

Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut

By Vandana Singh

Today, 10:39 PM

Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million. The…

PAIC

Latest news

Petra Acquisition M&A Partner Revelation Biosciences Announces Initiation Of Phase 1b Clinical Study Of REVTx-99 For Experimental Treatment Of Allergic Rhinitis And Chronic Nasal Congestion

Petra Acquisition Corp. SPAC Merger Partner, Revelation Biosciences, Reports Received Approval To Initiate Phase 2b Viral Challenge Study Of REVTx 99 For Treatment To Prevent Respiratory Viral Infections

Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut